Breaking News, Collaborations & Alliances

PTC Therapeutics Achieves BMI1 Milestone

PTC Therapeutics, through its Wellcome Trust collaboration, has identified a chemical series of molecules that penetrates the blood-brain barrier in animal models and reduces levels of BMI1, a protein linked to drug-resistant cancers.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

PTC Therapeutics, through its Wellcome Trust collaboration, has identified a chemical series of molecules that penetrates the blood-brain barrier in animal models and reduces levels of BMI1, a protein linked to drug-resistant cancers. The milestone triggers a $2.2 million payment to PTC. The Wellcome Trust awarded PTC $5.4 million to support the development of drugs that target BMI1 back in June 2010. PTC identified the lead chemical series using its screening technique GEMS. The goal of the ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters